logo
Plus   Neg
Share
Email

ObsEva Names David Renas CFO - Quick Facts

ObsEva SA (OBSV) said Monday that it has appointed David Renas as Chief Financial Officer and member of the company's Executive Committee, effective today. He will be based in the U.S.

Renas has more than 30 years of financial and legal experience, including 15 years within the pharmaceutical and life sciences industry. Most recently, he served as CFO at Petra Pharma and CFO and General Counsel at Sangart.

He also served as a Partner at Adkins Black LLP. He was an attorney in private practice with Gray Cary Ware & Freidenrich and Foley & Lardner, and a CPA at Deloitte.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
RELATED NEWS
Follow RTT